Keytruda/Inlyta combo shows significant survival benefit in kidney cancer trial - PharmaTimes

MSD says the KEYNOTE-426 met both primary endpoints in demonstrating statistically significant and clinically meaningful increases in OS and PFS in the first-line treatment of advanced or metastatic renal cell carcinoma (RCC), compared to sunitinib monotherapy.

The study also met the key secondary endpoint of objective response rate (ORR), with significant improvements for the Keytruda (pembrolizumab)/Inlyta (axitinib) combination compared with sunitinib.

Results for OS, PFS and ORR were consistent regardless of PD-L1 expression and across all risk groups, while the safety profile of the combination "was generally consistent with that observed in previously reported studies for each therapy," MSD noted.

The results are to be presented at an upcoming medical meeting and submitted to regulatory authorities worldwide.

-----------------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.